A Phase III Randomized Equivalence Study of Biosimilar Filgrastim versus Amgen Filgrastim in Patients Receiving Myelosuppressive Chemotherapy for Breast Cancer
Authors:
- Cornelius F. WallerCWCornelius F. Waller
- Vladimir F. SemiglazovVSVladimir F. Semiglazov
- Sergei TjulandinSTSergei Tjulandin
- Dmitry BentsionDBDmitry Bentsion
- Stephen ChanSCStephen Chan
- Rodeina ChallandRCRodeina Challand
- 6 September 2010
- journal article
- research article
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 33 (10) , 504-511